Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

References

• Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19
   PubMed Web of Science ®Google Scholar
• Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007;87:507-20
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N,. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 2004;27:17-20
   PubMed Web of Science ®Google Scholar
• Stonehouse A, Okerson T, Kendall D,. Emerging incretin-based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev 2008;4:101-9
   PubMedGoogle Scholar
• Gastaldelli A, Ferrannini E, Miyazaki Y,. Thiazolidinediones improve β-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871-83
   PubMed Web of Science ®Google Scholar
• Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004;53(Supp 3):S190-96
   Web of Science ®Google Scholar
• Vilsboll T, Krarup T, Madsbad S,. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002;45:1111-9
   PubMed Web of Science ®Google Scholar
• Parkes D, Jodka C, Smith P,. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001;53:260-7
   Web of Science ®Google Scholar
• Goke R, Fehmann HC, Linn T,. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-5
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J,. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J,. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J,. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Durán García S,. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL,. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Herman GA, Stevens C, Van Dyck K,. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88
   PubMed Web of Science ®Google Scholar
• Mu J, Woods J, Zhou YP,. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-704
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc 2007;298:194-206
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, et al. Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9: 194-205.
   Google Scholar
• Gedulin B, Tatarkiewicz K, Smith P,. Contrasting actions of sitagliptin and exenatide on food intake, body weight, glucose stimulated insulin secretion and gastric emptying in rodents. Diabetologia 2007;50(Supp 1):S239
   Web of Science ®Google Scholar
• Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat-fed mice. Diabetes 2008;57:190-8
   PubMed Web of Science ®Google Scholar
• Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008 [doi: 10.1111/j.1463-1326.2007.00836.x]
   Google Scholar
• Kolterman OG, Kim DD, Shen L,. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm 2005; 62:173-81
   PubMed Web of Science ®Google Scholar
• Anon. World Medical Association declaration of Helsinki: recommendations guiding medical physicians in biomedical research involving human subjects. J Am Med Assoc 1997; 277:925-6
   PubMed Web of Science ®Google Scholar
• Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996; 50:253-64
   PubMed Web of Science ®Google Scholar
• Anon. American Diabetes Association: clinical practice recommendations 2008. Diabetes Care 2008;31(Supp 1):S12-54
   Google Scholar
• Anon. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Supp 7):3-68
   Google Scholar
• Anon. International Diabetes Federation: guideline for management of postmeal glucose. 2007. p. 1-32.
   Google Scholar
• Cervera A, Wajcberg E, Sriwijitkamol A,. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008; 294: E846-52
   PubMed Web of Science ®Google Scholar
• Maggs D, MacDonald I, Nauck MA. Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. Diabetes Obes Metab 2008;10:18-33
   PubMed Web of Science ®Google Scholar
• Qin X, Shen H, Liu M,. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288:G943-9
   PubMed Web of Science ®Google Scholar
• Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007; 293: R983-7
   PubMed Web of Science ®Google Scholar
• Edwards CM, Stanley SA, Davis R,. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281:E155-61
   PubMed Web of Science ®Google Scholar